inavir sales 3.9bn yen, page-35

It appears only Biota shareholders on HC understand the importance of the Inavir sale results. No matter how excited we are, the market is not impressed, WHY?

The quarterly results announced was:
3.9B yen = AUD45.2m
Royalty = AUD1.6m
Royalty % = 3.5%

DS forecast 9 B yen sale for 2011 = AUD 104.3 m
Royalty = AUD 3.6 m for the whole year.

BTA other income comes from GSK sales of Relenza which had sunk to an all time low of less than 5% of the market share despite PC collecting 0.5 million of free oopies for normalising relationship with GSK

BTA shareholders have to wonder why PC has not explain to the market the significance of the Inavir sales.




Is it in PC interest to excite the market? Very soon on June 30th PC is going to collect his free oopies. The number of oopies he collects depend on the BTA share price on 30 June.

Quoting page 17 of the 2010 annual report on the Equity Retention Incentive: At 100%, the incentive is twice the value of the cash incentive, with the intermediate steps between 50% and 100% increasing logarithmically, from zero times the cash incentive at 50% to twice the cash incentive at 100%. Based on this calculation un-issued ordinary shares at an issue price equal to the Company�s share price on the allocation date, normally on 30 June, are allocated to the individual.

BTA shareholders, take a guess - will PC get more free oopies at mid $1.50 or at $2.00 sp?

The only publicly available video on PC promoting Relenza is the one he uploaded onto the internet during the swine flu outbreak. The timing was very strange indeed as at that particular time, the demand for Relenza out stripped GSK production capacity. So why promote Relenza at the time when GSK could not meet market demand.
Why is PC not promoting Relenza now or promoting Inavir.
Will PC get more free oopies on June 30th from a soaring sp in the mid $2.50 or at the low $1.50? Is the answer obvious?